STOCK TITAN

Vivos Therapeutics (VVOS) Stock News, Jul-Sep 2021

VVOS NASDAQ

Vivos Therapeutics, Inc. develops and commercializes medical technology and healthcare services for breathing-related sleep disorders, including obstructive sleep apnea and snoring associated with dentofacial abnormalities. Its Complete Airway Repositioning and Expansion (CARE) oral devices have FDA 510(k) clearances for adult OSA patients across severity levels and for moderate-to-severe OSA in children ages 6 to 17.

Company news commonly covers financial results, sleep testing services, treatment-center activity, and the integration of The Sleep Center of Nevada operating assets. Updates also address the shift toward a medical-affiliation distribution model, payer-network status for supported professional practices, collaborations for airway and sleep technologies, and capital actions such as warrant exercises and private placements.

Rhea-AI Summary

Vivos Therapeutics (NASDAQ: VVOS) has established the Vivos Medical Consortium to enhance research in managing obstructive sleep apnea (OSA). Co-chaired by Dr. Clete Kushida from Stanford and Dr. Cecilia Wu from the University of Alberta, the consortium comprises specialists from various medical fields. The group's goal is to improve physician-dental collaboration and explore new applications for Vivos' OSA technology, which has shown promising results. Vivos aims to facilitate broader adoption of its innovative, non-invasive therapies for patients with OSA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
none
-
Rhea-AI Summary

Vivos Therapeutics, Inc. (NASDAQ: VVOS), a company focused on innovative treatments for sleep-disordered breathing, will present at the Benzinga Healthcare Small Cap Conference on September 29, 2021, at 2:20 pm EST. The presentation will be led by Chairman Kirk Huntsman and CFO Brad Amman. Interested investors can register for a free spectator pass. Vivos offers non-surgical solutions for obstructive sleep apnea through its Vivos System, which has helped over 19,000 patients globally. A replay will be available on their website post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
conferences
-
Rhea-AI Summary

Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced that CEO Kirk Huntsman will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 am EDT. Investors can register for the event and listen to the presentation via provided links. Vivos specializes in innovative treatments for mild-to-moderate obstructive sleep apnea (OSA), offering solutions like the Vivos System, which has aided over 19,000 patients worldwide. A replay of the presentation will be available on Vivos’ website post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.22%
Tags
conferences
Rhea-AI Summary

Vivos Therapeutics (NASDAQ: VVOS) has announced a partnership with Empower Sleep to enhance diagnostic and consultation services for obstructive sleep apnea (OSA) patients in North America. This partnership aims to leverage their technologies for improved patient screenings and treatments using Vivos' VivoScore product. Recent data shows that 56% of patients tested by Vivos dentists received positive OSA diagnoses, with 50% entering treatment. The collaboration seeks to increase access to personalized telemedicine care, addressing the needs of patients intolerant to traditional CPAP devices.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.20%
Tags
none
-
Rhea-AI Summary

Vivos Therapeutics has received FDA 510(k) market clearance for its mmRNA device, a non-invasive treatment for mild to moderate obstructive sleep apnea (OSA). This approval increases the potential for insurance reimbursement, including Medicare. With over 54 million Americans affected by sleep apnea, Vivos aims to provide a cost-effective alternative to current treatments. The company also plans to appeal the FDA's denial of its DNA appliance application, although this is not expected to impact existing operations significantly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
53.65%
Tags
-
Rhea-AI Summary

Vivos Therapeutics (NASDAQ: VVOS) has released detailed results from a national study on its FDA Class 1 DNA appliance for sleep-disordered breathing. The data indicates that one in four patients reported complete resolution of obstructive sleep apnea (OSA) symptoms. Among 20 patients with severe OSA, average improvement in AHI scores was 53%, with none reporting worsening symptoms. The average improvement for 18 patients with moderate OSA was 64%. The results highlight the effectiveness of Vivos' treatment protocols compared to traditional methods.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
none
Rhea-AI Summary

Vivos Therapeutics reported a 37.5% increase in Q2 revenue, reaching $4.5 million, and a 30% rise from Q1 2021. Gross profit for Q2 was $3.6 million, with an 81% gross margin. However, the company faced a net loss of $4.0 million for the quarter, up from $1.4 million in Q2 2020. Vivos has treated over 19,000 patients and opened a training center in Denver. New initiatives, including the VivoScore test, have shown a significant increase in sleep apnea testing, indicating expanding market adoption.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.34%
Tags
-
Rhea-AI Summary

Vivos Therapeutics, Inc. (NASDAQ: VVOS) will present at the Q3 Virtual Investor Summit on August 18, 2021, at 9:30 am EST. The presentation will feature CEO Kirk Huntsman, CFO Brad Amman, and Investor Relations Officer Ed Loew. Vivos focuses on developing innovative treatments for sleep-disordered breathing, including obstructive sleep apnea (OSA). The company’s Vivos System offers a non-invasive, cost-effective solution using customized oral appliances, proven effective in over 19,000 patients globally. Interested investors can register for the presentation online.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.10%
Tags
conferences
-
Rhea-AI Summary

Vivos Therapeutics (NASDAQ: VVOS) will release its second-quarter financial results after market close on August 12, 2021, with a conference call scheduled for 5:00 p.m. ET the same day. This call will cover the company's financial performance, recent milestones, and growth strategy. Vivos specializes in innovative treatments for sleep-disordered breathing, particularly obstructive sleep apnea. The company offers the Vivos System, a non-invasive oral appliance treatment that has benefitted over 19,000 patients worldwide through 1,250 dentists.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.70%
Tags
conferences earnings date
Rhea-AI Summary

Vivos Therapeutics has announced the opening of The Vivos Institute in Denver, Colorado. This 15,000-square-foot training facility aims to significantly enhance education for healthcare providers on treating obstructive sleep apnea (OSA). The Institute can train 300 to 400 professionals daily, offering hands-on education about OSA and Vivos’ treatments. Key funding of over $500,000 in equipment was donated by dental and medical supply companies. The opening is part of Vivos' mission to improve awareness and treatment options for sleep-disordered breathing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
none

FAQ

What is the current stock price of Vivos Therapeutics (VVOS)?

Vivos Therapeutics (VVOS) last closed at $0.0540.

What is the market cap of Vivos Therapeutics (VVOS)?

The market cap of Vivos Therapeutics (VVOS) is approximately $1.8M.